Kevin Lee Sells 9,038 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) CEO Kevin Lee sold 9,038 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $127,345.42. Following the completion of the transaction, the chief executive officer now directly owns 495,026 shares in the company, valued at $6,974,916.34. This represents a 1.79 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Bicycle Therapeutics Trading Down 0.1 %

Shares of Bicycle Therapeutics stock traded down $0.01 during trading hours on Monday, reaching $14.88. The stock had a trading volume of 289,310 shares, compared to its average volume of 435,603. The stock’s 50 day moving average is $19.27 and its 200 day moving average is $21.86. Bicycle Therapeutics plc has a twelve month low of $12.17 and a twelve month high of $28.67. The firm has a market capitalization of $1.03 billion, a PE ratio of -4.52 and a beta of 0.92.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The company had revenue of $2.68 million during the quarter, compared to analysts’ expectations of $6.82 million. During the same quarter in the prior year, the firm posted ($1.26) EPS. Bicycle Therapeutics’s quarterly revenue was down 50.0% compared to the same quarter last year. As a group, sell-side analysts predict that Bicycle Therapeutics plc will post -3.05 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Natixis Advisors LLC acquired a new position in Bicycle Therapeutics during the second quarter worth $261,000. TD Asset Management Inc raised its position in shares of Bicycle Therapeutics by 76.7% during the 2nd quarter. TD Asset Management Inc now owns 97,186 shares of the company’s stock worth $1,967,000 after purchasing an additional 42,200 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Bicycle Therapeutics by 97.2% in the 2nd quarter. Renaissance Technologies LLC now owns 326,800 shares of the company’s stock valued at $6,614,000 after buying an additional 161,100 shares in the last quarter. L & S Advisors Inc boosted its holdings in Bicycle Therapeutics by 16.1% in the 2nd quarter. L & S Advisors Inc now owns 58,335 shares of the company’s stock worth $1,181,000 after buying an additional 8,075 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in Bicycle Therapeutics during the 2nd quarter worth approximately $206,000. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Wall Street Analysts Forecast Growth

BCYC has been the topic of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicycle Therapeutics in a research report on Monday, September 9th. B. Riley dropped their price objective on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Needham & Company LLC reissued a “buy” rating and set a $38.00 target price on shares of Bicycle Therapeutics in a report on Thursday, October 31st. Stephens initiated coverage on shares of Bicycle Therapeutics in a report on Friday, November 8th. They issued an “equal weight” rating and a $25.00 price target on the stock. Finally, JMP Securities reduced their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research note on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $35.25.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.